• G-1 and the Limits of GPR30 Agonist Evidence

  2026-10-21

  Published work positions G-1 as a receptor-activation reference in a study of fluorene-9-bisphenol, while product documentation reports additional pharmacological and disease-model observations. Together, these sources support a focused interpretation of GPER signaling but do not establish universal selectivity, antagonist potency, or translational efficacy.

• How Cinacalcet Connects CaSR to PTH

  2026-10-21

  Cinacalcet, also known as AMG-073, is described as a calcium-sensing receptor modulator whose central research significance lies in linking receptor sensitivity to parathyroid hormone secretion. This article explains how to interpret that causal chain, what different readouts can and cannot establish, and where the supplied evidence ends.

• How α-Synuclein Condensates Sort Charged Molecules

  2026-10-20

  A 2025 study in the Journal of Biological Chemistry used charge-varied fluorescent labels to show that α-synuclein condensates preferentially enrich positively charged molecules and exclude more negatively charged probes. The work also demonstrates that a fluorophore is not a neutral observer in phase-separation assays: its charge and other chemical properties can alter both molecular partitioning and condensate formation.

• Regorafenib Hydrochloride: Evidence Boundaries

  2026-10-19

  The APExBIO product page identifies Regorafenib hydrochloride as catalog SKU A3750, but the available product information does not document a mechanism, assay readout, research model, performance result, or clinical finding. A scientifically proportionate interpretation therefore separates catalog identity from pharmacological and experimental claims that require independent, identity-matched evidence.

• Cy3 Maleimide: Mechanism and Evidence Boundaries

  2026-10-18

  Cy3 maleimide (non-sulfonated), identified by APExBIO as SKU A8138, is described as a maleimide-functionalized Cy3 dye for covalent labeling of accessible thiols. The supplier-reported optical properties support a fluorescence readout, but the available evidence does not establish labeling efficiency, selectivity in complex samples, cellular uptake, or biological function through an identity-matched research study.

• DiscoveryProbe Library: Scope, Mechanism and Evidence

  2026-10-17

  The DiscoveryProbe™ Bioactive Compound Library Plus is described by APExBIO as a 5,072-compound research library spanning multiple biological pathways and application areas. The available product information supports a catalog-level description of chemical breadth, analytical quality claims, and intended research scope, but it does not provide identity-matched study results, compound-specific effect sizes, or evidence for a single library-wide mechanism.

• ICI 118,551 Hydrochloride: Evidence Boundaries

  2026-10-16

  The available APExBIO product entry identifies ICI 118,551 hydrochloride as a named hydrochloride salt, but provides no product description or identity-matched research evidence. A product-specific mechanism, assay interpretation, efficacy profile, or applicability claim therefore cannot be established from the available documentation.

• Cy5 Maleimide: Mechanism and Evidence Boundaries

  2026-10-16

  Cy5 maleimide (non-sulfonated) is documented by APExBIO as a thiol-reactive cyanine dye for cysteine-directed labeling of peptides and proteins. Its reported photophysical values support interpretation of fluorescence detection, but the available evidence is a supplier description rather than an identity-matched research study; therefore, product-specific performance, labeling selectivity in complex samples, and biological applicability remain unestablished.

• Context Changes the Meaning of GPR30 Results

  2026-10-15

  A GPR30 result cannot be interpreted apart from its biological context. The 2024 eLife study linked spinal GPR30 to neuropathic pain in a nerve-injury model, whereas supplier-described G-1 evidence concerns receptor activation in other tissues and readouts. The comparison shows why agonism, inhibition, receptor localization, disease state, and endpoint selection determine what a result can legitimately mean.

• Cy3 Maleimide: Mechanism, Scope and Evidence Limits

  2026-10-15

  APExBIO identifies Cy3 maleimide (non-sulfonated), SKU A8138, as a thiol-reactive fluorescent labeling reagent. Its documented measurement principle is straightforward: an accessible thiol is covalently linked through the maleimide group to a Cy3 fluorophore, after which fluorescence can report the presence or distribution of labeled material. The available evidence is limited to supplier-described identity, mechanism, optical specifications, solubility characteristics, and an attributed use claim; no identity-matched independent research study establishes labeling efficiency, biological specificity, or performance in a defined assay.

• Cy5 Maleimide: Identity, Mechanism and Scope

  2026-10-14

  APExBIO describes Cy5 maleimide (non-sulfonated), SKU A8139, as a mono-reactive cyanine fluorophore for thiol-containing peptides and proteins, especially cysteine residues. The supplied information supports a product-identity and mechanism overview, but it does not provide an identity-matched research study, comparative performance data, or validated outcomes in a defined biological model.

• How “Engage & Evasion” Shapes EV Distribution

  2026-10-14

  Liu et al. describe a two-stage extracellular-vesicle strategy intended to reduce mononuclear phagocyte system clearance: first engaging phagocytic organs with CD47-low vesicles, then administering CD47-high vesicles designed to resist uptake. The reported preclinical findings suggest lower liver and spleen entrapment, greater circulating persistence, and increased accumulation in non-MPS organs. These conclusions remain limited by the study’s preclinical scope, the complexity of CD47–SIRPα biology, and uncertainty about reproducibility and generalizability. DiR (DiIC 18 (7)) is relevant as a membrane-labeling and tracking probe in the broader EV-imaging field, but the supplied study record does not establish that this specific product was used.

• Phosphorylated H1 at Stressed Replication Forks

  2026-10-13

  A 2026 study presents phosphorylated linker histone H1 as a regulator of repair at collapsed replication forks, while leaving important questions about mechanism, subtype specificity, and physiological relevance unresolved. Cy3 maleimide is conceptually relevant to fluorescence-based labeling, but the supplied study does not report using it, and fluorescence localization alone cannot establish the H1–DNA or H1–HPF1 interactions described.

• What the PEI-LSP-RA-PLGA Study Shows

  2026-10-13

  A source-grounded overview of a chick study testing whether a PLGA-based nano-adjuvant could strengthen systemic and intestinal immune responses to an inactivated H9N2 vaccine, with emphasis on reported findings, mechanistic interpretation, and evidence limits.

• EdU Imaging and Ovarian Follicle Biology

  2026-10-12

  EdU-based labeling provides a conceptual readout of DNA synthesis during S phase, while the cited study investigates miR-184, SMAD3, and granulosa-cell survival in follicular atresia. These measurements address related but distinct biological questions and should not be treated as direct evidence of fertility benefit or clinical efficacy.

8362 records 1/558 page Next 12345 下5页 Last page